NDTMS data on club drugs and NPS• Historically, the NDTMS Core Data Set has added individual substances to the list of

available drug codes with each refresh

• Mephedrone was added to the CDS in 2010/11, so we now have three years’ worth of data, as well as data on more established club drugs (ecstasy, ketamine etc.)

• For 2013/14, we have added a series of new codes which describe NPS by their effects rather than naming individual substances:

8800 NPS Other – predominantly stimulant

8801 NPS Other – predominantly hallucinogenic

8802 NPS Other – predominantly dissociative

8803 NPS Other – predominantly sedative or opioid

8804 NPS Other – predominantly cannabis

8805 NPS Other – effects different to available classifications or not stated

1 Treatment data on club drugs and NPS

NTA published a report on trends in club drug use in November 2012• Definition of ‘club drug user’ in this report was any person in treatment since

2005/06 citing any of the following substances: Ecstasy

Ketamine

GHB/GBL

Methamphetamine

Mephedrone (since introduction to CDS in 2010/11)

• Estimated one million people in England and Wales used one or more of the above in 2011/12 (CSEW)

• 4,500 over-18s and 2,000 under-18s in treatment for club drugs in 2011/12

• 4% of all new over-18s and 10% of all new under-18s in 2011/12

2 NDTMS data on club drugs and NPS

NTA published a report on trends in club drug use in November 2012• General increasing trend, driven by increasing ketamine presentations and

introduction of mephedrone. Ecstasy presentations have declined since 2005/06, but are starting to flatline

3 NDTMS data on club drugs and NPS

NTA published a report on trends in club drug use in November 2012• Relatively likely to leave treatment successfully and completion rates are

improving over time

• ‘Tend to be a group whose level of functioning is quite high’

4 NDTMS data on club drugs and NPS

Treatment data on club drugs/NPS and injecting• Club drugs report highlighted that rates of injecting among club drug users

increased from 6% to 8%, bucking the general decreasing injecting trend

• Can be difficult to determine definitively from NDTMS data if people are injecting these drugs, particularly where reported adjunctively to heroin

• However, particularly high rates observed among methamphetamine users (22%) and GHB users (11%), even where these were the only reported substances

• Up to this point, relatively low rates of injecting reported among clients in treatment for mephedrone (5%) – although much higher where heroin use also indicated

5 NDTMS data on club drugs and NPS